Deutsche Bank AG restated their buy rating on shares of AstraZeneca plc (LON:AZN) in a research report released on Wednesday morning. The firm currently has a GBX 5,500 ($67.93) target price on the biopharmaceutical company’s stock.

Several other research analysts have also recently commented on the stock. Jefferies Group LLC boosted their price target on shares of AstraZeneca plc from GBX 5,250 ($64.84) to GBX 5,350 ($66.07) and gave the stock a buy rating in a report on Thursday, March 9th. Liberum Capital reiterated a buy rating and set a GBX 5,100 ($62.99) price target on shares of AstraZeneca plc in a report on Thursday, March 9th. Barclays PLC began coverage on shares of AstraZeneca plc in a report on Wednesday, March 8th. They set an overweight rating and a GBX 6,000 ($74.10) price target for the company. Bryan, Garnier & Co reiterated a buy rating and set a GBX 5,400 ($66.69) price target on shares of AstraZeneca plc in a report on Tuesday, February 28th. Finally, Shore Capital reiterated a sell rating on shares of AstraZeneca plc in a report on Tuesday, February 28th. Four investment analysts have rated the stock with a sell rating, eight have given a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company’s stock. AstraZeneca plc has a consensus rating of Hold and a consensus target price of GBX 5,018.36 ($61.98).

Shares of AstraZeneca plc (LON:AZN) opened at 4900.00 on Wednesday. The stock has a 50 day moving average of GBX 4,617.49 and a 200-day moving average of GBX 4,602.58. The firm’s market cap is GBX 62.00 billion. AstraZeneca plc has a 1-year low of GBX 3,680.00 and a 1-year high of GBX 5,505.00.

Your IP Address:

The company also recently disclosed a dividend, which was paid on Monday, March 20th. Shareholders of record on Thursday, February 16th were given a dividend of GBX 150.20 ($1.86) per share. The ex-dividend date of this dividend was Thursday, February 16th. This represents a yield of 3.52%. This is an increase from AstraZeneca plc’s previous dividend of $68.70.

AstraZeneca plc Company Profile

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.

Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with Analyst Ratings Network's FREE daily email newsletter.